Metrion Biosciences Ltd.. (11/25/24). "Press Release: Metrion Biosciences Appoints Lee Patterson as CEO". Cambridge.

	Product	contract research (drugs)
	Product 2	drug discovery services

Significant CRO C-suite experience expected to drive growth and commercial expansion into global markets

Metrion Biosciences (“Metrion”), the specialist preclinical contract research organisation (CRO) and a leader in ion channel screening, today announced the appointment of Lee Patterson as its new CEO, effective from 2nd December 2024. An experienced life sciences and CRO executive, Lee will guide the Company as it seeks to execute an ambitious growth strategy, enhancing its specialist services and expanding further in key global markets. He succeeds Dr Andrew Southan, who has decided to step down as CEO after five years in the post.

A renowned leader in the sector, Lee Patterson specializes in steering preclinical CROs to implement robust and effective plans for long-term commercial growth. Previously CEO at Charnwood Discovery, a provider of integrated drug discovery services with a global biotech and pharma client base, he led the company through its successful acquisition by Concept Life Sciences in October 2024. Prior to this, Lee served as Chief Operating Officer at Quanticate, a global biometrics CRO, and Chief Operating Officer at Concept Life Sciences. He also held several executive roles at Covance/Labcorp, the most recent being Executive Director, Global Operations and Early Development Management Office.

Lee will join recently appointed CCO Dr Chris Mathes as the latest addition to Metrion’s senior leadership team1. Working closely alongside Chris and the broader management team, Lee’s C-suite level expertise and experience will support Metrion to bolster its global commercial presence and scientific capabilities.

Outgoing CEO Dr Andrew Southan has led Metrion successfully since 2019, more than doubling revenues over that time and overseeing the Company’s growth in staffing, laboratory facilities and international client base. He also led the Company’s successful £3.7M equity financing round in December 2023.

“On behalf of the Board and management team, I would like to thank Andy Southan for his dedicated leadership over the last five years, in particular establishing Metrion’s reputation as a high quality, specialist CRO and a leading centre of expertise in ion channel biology,” said Keith McCullagh, Chairman, Metrion Biosciences. “At the same time, I welcome Lee Patterson to the Company. His experience of leading commercial CROs and his expertise in enhancing operational efficiencies are both outstanding and we look forward to working with him to continue Metrion’s growth as a specialist CRO serving global markets.”

Lee Patterson, CEO, Metrion Biosciences, commented: “Metrion Biosciences has built an impressive reputation in ion channel drug discovery, with proven commitment to outstanding customer service and world class science. I am excited to join this talented team and look forward to working with them to enhance and expand our specialised services to meet the needs of our clients worldwide.”

1. Press Release (23rd July, 2024): Metrion Biosciences appoints Dr Chris Mathes as Chief Commercial Officer

-ENDS-

Notes to Editors

[photos]

Lee Patterson, CEO,
Metrion Biosciences

Keith McCullagh, Chairman,
Metrion Biosciences

For high resolution images please contact Zyme Communications.

For further information please contact:

Katie Odgaard
Zyme Communications
E-mail: katie.odgaard@zymecommunications.com
Tel: +44 (0)7787 502 947

Sue Peffer
Metrion Biosciences
E-mail: sue.peffer@metrionbiosciences.com

About Metrion Biosciences

Metrion Biosciences is a specialist preclinical drug discovery contract research organization (CRO) and drug discovery business. The Company provides customers with access to a range of high-quality ion channel assays including an industry leading panel of in vitro cardiac safety assays, high-throughput screening, and translational research such as native cell and phenotypic assays for neurological and cardiotoxicity testing. Metrion also provides neuroscience focused assays with brain slices, DRG neurons, and other primary neurons.

Metrion’s leadership has extensive and in-depth experience, offering careful interpretation of experimental findings, communicating results and providing strategic recommendations to support decision making to best inform screening strategy. Acting as an extension of our clients’ research teams, Metrion provides tailored assay formats, quality assured data packages and traditional or bespoke and novel studies on a fee-for-service or collaboration basis.

For more information, please visit www.metrionbiosciences.com
LinkedIn: @metrion-biosciences | X: @metrion_biosci

Record changed: 2024-11-28

Picture EBD Group Biotech Showcase 2025 San Francisco BTS25 650x200px

To subscribe to our free, monthly mass spectrometry newsletter, please send an e-mail to info@iito.de and simply fill the subject line with the word »MSC Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the Eurpean life sciences and the life sciences in German-speaking Europe (DE, AT & CH) at Life-Sciences-Germany.com and Life-Sciences-Europe.com